Colorectal Cancer | Unmet Need | US/EU | 2016
Several therapies are available for treatment of second- and subsequent-line advanced/ metastatic colorectal cancer that have a positive effect of patient survival, but none of them are able to cure the disease. Furthermore, some therapies used are associated with side effects that can significantly decrease patients’ quality of life and can also prevent patients from receiving treatment. Hence, there is an unmet need for novel efficacious therapies with an improved safety and tolerability profile, and this Unmet Need module examines the key drivers of prescribing in this indication and analyses significant commercial opportunities.
Related Market Assessment Reports
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
